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Hyperhidrosis (HH) is excessive sweating that usually
interferes with the patient’s social life. In more than 80% of
the cases, the symptoms start in childhood. Early detection
and management can significantly improve the patient’s
quality of life; however, HH remains widely underdiagnosed
and undertreated, particularly among children. Many
patients do not realize that they have a treatable condition
and reports have shown that only 38% of the patients had
discussed their condition with a healthcare professional.
The aim of this article was to improve awareness on the
significant sequel of HH in children and highlight its effects
on their quality of life and various available treatment
options. Ann Pediatr Surg 11:169–172 c 2015 Annals of
Pediatric Surgery.
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Introduction
Hyperhidrosis (HH) is a condition characterized by
excessive sweating than that required for normal tem-
perature regulation. It can be very distressing, with
significant negative impacts on the patient’s social life [1].
In the paediatric population, HH is usually an under-
recognized problem [2]. The aim of this article was to
highlight the significance of HH in the paediatric
population, its effects on their quality of life (QoL) and
different available treatment options.
Types/sites
HH can either be primary (essential) or secondary.
Primary HH is defined as ‘excessive function of the
sudomotor sweat control system, in the absence of a
sweating trigger’. However, in secondary HH, the
excessive sweating occurs in response to a stimulus such
as medication, anxiety and neurological or endocrine
disorders [3]. HH can affect the axilla (axillary HH),
palms (palmar HH), feet (plantar HH), face (craniofacial
HH) or diffuse (generalized HH) [3].
Epidemiology
The estimated prevalence of HH in the USA is 2.8%,
with more than half of these individuals having axillary
HH [4]. Although there are few reports of HH in the
paediatric population, many adult sufferers admit to an
early onset of symptoms. Lin and Fang [5] described
surgery for HH in 1360 patients, with 81.5% reporting
symptoms since childhood, 15.9% since adolescence, and
2.6% reporting symptoms since adulthood. Authors have
reported positive family history in 25–50% of patients
with palmar HH, which may suggest autosomal dom-
inance inheritance [3].
Pathogenesis
Sweating is important for regulating the body tempera-
ture by sweat evaporation from the eccrine glands, which
are believed to be the source of primary HH. Thermal
sweating is controlled by the hypothalamus, and emo-
tional sweating is regulated by the cerebral cortex [2].
Causes
The aetiology of primary HH is unknown and could be
related to abnormal response to emotional stress. In
contrast, secondary HH usually has an underlying cause.
Examples of causes of secondary HH in children and
adolescents are listed in Table 1 [2].
Diagnosis
The recommended criteria for the diagnosis of primary
focal HH are idiopathic excessive focal sweating for a
minimum of 6 months. This should be associated with a
minimum of two of the following characteristics: (i)
bilateral and relatively symmetrical distribution; (ii)
interference with daily activities; (iii) onset before 25
years of age; (iv) incidence of at least one episode weekly;
(v) positive family history; or (vi) cessation of sweating
during sleep [6].
In contrast, generalized sweating can continue during
sleep and has an identifiable underlying cause [2]. A
detailed history and physical examination should aim at
exploring the causes of secondary sweating, listed
in Table 1 [2].
Complications of hyperhidrosis and its effect
on quality of life
HH is always accompanied by subjective reduction in
QoL for the patient, who will almost inevitably feel
uncomfortable in a world where sweating is considered
antiaesthetic and may thereby affect socialization.
Wolosker et al. [7] have observed that, although these
patients do not present any risk for death or organ failure,
the reduction in QoL can have serious consequences. In
some cases, it may not only cause anxiety and distress but
can also be incapacitating and even pose high risks for
some professionals, such as police officers, who manip-
ulate weapons, and electricians, who handle electric
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material [7]. A national survey by Strutton et al. [4], in
2004, in the USA showed that one-sixth of responders
reported sweating that was either ‘barely tolerable and
frequently interfered’ or was ‘intolerable and always
interfered’ with their daily activities. In children with
HH the symptoms can cause significant social and
psychological handicap, which may impair school perfor-
mance and affect their social lives [1].
Treatment
Many patients do not realize that they have a treatable
condition. According to Strutton et al. [4], only 38% of
patients had discussed their condition with a healthcare
professional. Early detection and management can
significantly improve a patient’s QoL; nonetheless, HH
remains widely underdiagnosed and undertreated, parti-
cularly among paediatric patients [8].
Benefits, limitations and complications of different
treatment options are outlined below.
Topical therapy
Topical therapy can be used in the treatment of axillary HH.
‘Aluminium salts are the most common active ingredient in
antiperspirants. Aluminium chloride is the form used in over-
the-counter antiperspirants, whereas aluminium chloride
hexahydrate is the more effective compound found in
prescription preparations [8]’. Different concentrations of
aluminium chloride are used. Higher concentrations usually
cause intolerable dermatitis, whereas lower concentrations are
more tolerable but less effective. The mechanism of action is
blockage of the eccrine sweat glands, thus leading to
degeneration of the sweat glands [8]. The use of topical
therapy for palmar and plantar HH is usually less effective [2].
Most of the practitioners use topical therapy as first-line
treatment in children because of its noninvasive nature,
despite lack of reports evaluating its efficacy and safety in
children [8]. Side effects of topical therapy include skin
irritation, messy and time-consuming application and
failure or inadequate response [8].
Anticholinergics
Anticholinergics decrease sweat secretion by competitive
inhibition of acetylcholine at the muscarinic receptor [9].
Oxybutynin has been used in the treatment of axillary
HH among adults, with satisfactory results in around 70%
of the cases [10]. Known side effects of anticholinergics
include dry mouth, headache and urinary retention [8,10].
Although oral anticholinergics are commonly used in
children with urinary symptoms, its use in children with
HH has not been adequately evaluated. Oral glycopyrro-
late is an anticholinergic used in children with excessive
salivation [11]. Its use in children with HH has been
retrospectively evaluated and the authors concluded that
a mean of 2 mg/day of oral glycopyrrolate improved HH in
90% of 31 treated children. Median age at the time of
prescription was 14.9 years. Dry mouth was noted in 26%
of patients and one patient had palpitations requiring
cessation of treatment. Patients were still taking the
medicine for up to 10 years and all patients experienced
recurrence within a day or two when the treatment was
discontinued, and families reported ‘recurrence of
sweating to baseline when administration of the medica-
tion was inadvertently forgotten’ [11]. Patients who were
tired of taking the medication for 7 years eventually
underwent thoracoscopic sympathectomy (TS) as a more
definite treatment for HH [11]. Another oral antic-
holinergic is glycopyrronium bromide, which has been
reported in adults with HH, and side effects have limited
the treatment in one-third of the patients [12]. Its use in
the paediatric population has not been evaluated.
Gabapentin
In a case report by Adams et al. [13], the anticonvulsant
gabapentin was used orally to treat HH secondary to
spinal cord injury in a 12-year-old girl. This provided
improvement in her sweating, but the dose had to be
increased with time and combined with propantheline
bromide to eventually control her symptoms. The
mechanism of action of gabapentin in HH is unknown,
and the authors stated that ‘it may affect some as yet
unidentified receptor site that is present both centrally
and peripherally, or it may affect a second messenger
system that is intimately involved in neuronal function’.
They recommended that it ‘may be a worthwhile
alternative for patients who do not respond to other
medications, or who cannot tolerate the side of effects of
these drugs’ [13].
Iontophoresis
Iontophoresis, which involves ‘introduction of ions into
the tissues using electric current’, has been used for the
treatment of HH since the 1930s [8]. Its mechanism of
action is thought to involve plugging of the eccrine ducts
by hyperkeratinization [14]. Recurrence is common after
stopping the treatment [15]. There are no studies that
examined its use in the paediatric population.
Botulinum toxin A
The botulinum toxin is produced by Gram positive
anaerobic bacteria known as Clostridium botulinum. It acts
within the nerve endings to block the cholinergic
transmission at the neuromuscular junction of sweat glands
by antagonizing the action of Ca+ + [16]. It has been used
Table 1 Principal causes of secondary hyperhidrosis in children and adolescents 2
Physiological causes Pathological causes
Hot weather Generalized HH Regional HH Focal HH
Exercise
Anxiety
Ingestion of spicy and
citrus food or alcohol
Obesity








(2) Reflex sympathetic dystrophy
(1) Frey syndrome
(2) Chorda tympani syndrome
(3) Gustatory sweating
HH, hyperhidrosis.
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in children with spastic cerebral palsy, strabismus and
spasmodic torticollis [16]. There have been only two case
reports describing the successful use of botulinum toxin in
children, one in a 13-year-old with palmar HH [17] and the
other was in a 14-year-old with axillary HH [16]. The main
side effect from the botulinum toxin injection is its short-
lived efficacy for around 6 months requiring retreatment,
which can result in atrophy of the underlying muscles [2].
Surgery
Overview
Surgery represents a safe, effective and long-lasting
treatment for HH in both children and adults [1]. The
current recommended surgical treatment by many
authors is TS [1]. Local procedures such as curettage or
liposuction have been used in axillary HH by some
authors who believe that it can provide long-term relief
from the excessive sweating while avoiding the compen-
satory sweating (CS) that is commonly seen with TS.
However, the main risks of these local procedures are
scarring, contractures and infections [8].
Sympathectomy, different techniques and results
Sympathectomy means destruction of the sympathetic
ganglia and chain, whereas sympathectomy refers to the
division of the sympathetic chain [18]. However, most
authors use the term sympathectomy for any sort of
interruption to the sympathetic chain [18].
In the past, sympathectomy was performed through
cervical or transaxillary open approach. In recent times,
minimally invasive approaches have been widely used for
the treatment of HH in both children and adults. Various
techniques have been described to interrupt the
sympathetic chain for treatment of HH, including
diathermy [19], chemical ablation [20], ultrasonic coagu-
lation [21], radiofrequency [22], transaction [23] or
thoracoscopic excision of the sympathetic chain [1].
TS is classically reserved for severe cases, after failure of
the conservative measures [3], although some authors have
recommended it as the first-line treatment for the severe
forms of palmar HH [1,22]. This usually involves division,
coagulation or excision of the second (T2) and/or the third
(T3) thoracic ganglia in palmar HH and the addition of the
fourth thoracic ganglia (T4) in axillary HH [1].
It has been suggested that more ‘aggressive’ approaches
for treating HH yield better results [1]. This is supported
by reports demonstrating higher satisfaction rates when
T2 and T3 were resected, in comparison with isolated T2
resection [24]. Authors have demonstrated higher recur-
rence rates following sympathectomy when compared
with sympathectomy, and higher recurrence following
one-ganglion resection in comparison with two-ganglion
resections [24]. Separation of the ends of the interrupted
sympathetic trunk was considered important to decrease
the risk for nerve regeneration following TS [5].
Compensatory sweating and quality of life after
thoracoscopic sympathectomy
CS is a common side effect following TS occurring
between 60 and 90% of the cases [1]. It usually appears
after 6 to 12 months, with the female population being
more susceptible to it, yet not related to the extension of
the sympathectomy [25].
In a report of 1360 patients following TS, CS was noted in
84% of them. The most common affected sites were the
back (82%) and the leg (78%). Only 3.5% of the patients
were more embarrassed by the CS when compared with
their original HH, and an overall 95% of the patients were
considered to have satisfactory results [5]. This is similar to
our experience in which CS was noted in two-thirds of the
patients following TS, yet none of them considered it as a
complication and all of the patients reported significant
improvement in their QoL. Overall, patients considered CS
as a minor inconvenience when compared with their original
sweating problem [1,21]. This is different from that reported
by Yano et al. [24], in which CS was noted in almost all of
their patients and was considered severe in 76% of them;
moreover, the intensity of CS did not change in the majority
of the cases and was related to hot weather and stress.
An assessment of the QoL before and after TS has
demonstrated that less than 10% of the patients were
dissatisfied and only 4% regretted the procedure [26].
Another report that evaluated the QoL at 30 days and 5
years after TS reported better QoL in more than 90% of
the patients, with around 1.5% reporting worse QoL
secondary to severe CS [7].
Conclusion
HH in children is a relatively common yet under-reported
problem that can cause a significant impact on the QoL.
Clinicians should be aware of this condition and have a
low threshold for referral for specialist treatment, which
has a high success rate.
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